OptiNose, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
OPTN Nasdaq 2834 www.optinose.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for OptiNose, Inc.

Optinose price target adjusted for stock split at Lake Street - Jan 17th, 2025 1:50 pm
Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million - Jan 15th, 2025 12:00 pm
Optinose Announces 1-for-15 Reverse Stock Split - Dec 26th, 2024 12:00 pm
Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference - Dec 2nd, 2024 8:53 pm
OptiNose, Inc. (NASDAQ:OPTN) Just Reported, And Analysts Assigned A US$3.50 Price Target - Nov 15th, 2024 12:25 pm
OptiNose Third Quarter 2024 Earnings: EPS: US$0.002 (vs US$0.083 loss in 3Q 2023) - Nov 14th, 2024 12:24 pm
OptiNose Inc (OPTN) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Revised Guidance - Nov 13th, 2024 7:06 am
Q3 2024 OptiNose Inc Earnings Call - Nov 13th, 2024 5:52 am
OptiNose (OPTN) Reports Break-Even Earnings for Q3 - Nov 12th, 2024 1:15 pm
Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights - Nov 12th, 2024 12:00 pm
Strength Seen in electroCore (ECOR): Can Its 6.0% Jump Turn into More Strength? - Nov 11th, 2024 9:13 am
Optinose Announces Reporting Date for Third Quarter 2024 Financial Results - Nov 5th, 2024 9:30 pm
Positive week for OptiNose, Inc. (NASDAQ:OPTN) institutional investors who lost 24% over the past year - Oct 19th, 2024 2:29 pm
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 16th, 2024 8:05 pm
OptiNose Inc (OPTN) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic Shifts Amid ... - Oct 9th, 2024 9:30 pm
Optinose Appoints Terry Kohler as Chief Financial Officer - Oct 7th, 2024 8:59 pm
OptiNose (NASDAQ:OPTN) shareholders have endured a 88% loss from investing in the stock five years ago - Sep 13th, 2024 3:36 pm
New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery - Sep 5th, 2024 1:00 pm
Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Aug 26th, 2024 1:00 pm
OptiNose Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Aug 10th, 2024 12:39 pm